Improving Outcome of Hodgkins Disease with Autologous Hematopoietic Stem Cell Transplantation

• DOI: 10.1007/s12288-015-0559-5
• Publication Date: 2015-05-29T10:54:34Z
• Authors: Shreeniwas Raut; Sandip Shah; Kamalesh Shah; Kinnari Patel; Shailesh Talati; Sonia Parikh; Asha Anand; Harsha Panchal; Apurva Patel; Akhil Jain
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

We report analysis of all consecutive Hodgkins disease patients undergoing autologous hematopoietic stem cell transplant from September 1999 to December 2014. Out of total 38 patients 26 were males and 12 were females. 32 were adults and 6 were pediatric (<18 years). None were elderly. Median age was 28 years (9-61). All received BEAM protocol as conditioning regimen. Median engraftment time for granulocytes was 12 and 14 days for platelets. Thirty three (86.84 %) patients achieved complete remission out of which 8 (24.24 %) had further relapse. Transplant related mortality occurred in 4 (10 %) patients. Finally 26 (78.78 %) patients were disease free at median follow up of 60 months and median disease free survival (DFS) was 35 months. DFS was 66.66 and 65 %, respectively on 3 and 5 years. While overall survival was 70.83 and 70 % on 3 and 5 years, respectively.